tbuckley/cabot-search huggingface dataset:
Loss of warfarin effect after occupational insecticide exposure
Authors: W. H. Jeffery
Journal: JAMA (1976)

NUMEROUS drugs have been reported to induce the metabolism of warfarin sodium,<sup>1</sup>and several chemicals in the environment are known to be inducers of oxidative drug metabolism.<sup>2</sup>There have been reports of enzyme induction in workers occupationally exposed to chlorinated hydrocarbon insecticides, in which the individuals were given test drugs, and half-lives were studied.<sup>3</sup> We report the case of a patient who demonstrated resistance to the hypoprothrombinemic effect of warfarin on two occasions after intense exposure to a chlorinated hydrocarbon insecticide mixture. <h3>Report of a Case</h3> A 53-year-old rancher was first admitted to Bernalillo County Medical Center, Albuquerque, NM, in December 1973, with the diagnosis of left femoral thrombophlebitis. He was treated with heparin sodium and warfarin and discharged taking warfarin sodium, 7.5 mg daily. His warfarin sodium dosage was increased to 10 mg alternating with 7.5 mg daily on Dec 28, 1973. On Jan 10, 1974,
THE PUBLIC HEALTH BILL.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
No plateau for HIV/AIDS epidemic in US women
Authors: P. Phillips
Journal: JAMA (1997)

TWO MAJOR messages emerged from the third National Conference on Women and HIV, held last month in Pasadena, Calif: Women have become the fastest-increasing new group of AIDS patients in the United States, and they as a group are being overlooked. The acquired immunodeficiency syndrome has become the third leading cause of death among women in the 25- to 44-year-old age group, and the disease ranks first as cause of death among African-American women in that group. See also p 1752. According to the Centers for Disease Control and Prevention (CDC), Atlanta, Ga, in the first 2 quarters of 1996, the estimated number of AIDS deaths was 13% lower than the estimated number of AIDS deaths in 1995. Deaths declined in men by 15% but increased among women by 3%. Earlier in the US epidemic, in 1985, women accounted for only 7% of cases; while in 1996, the percentage of
Conditioned Rflexes. An Investigation of the Physiological Activity of the Cerebral Cortex.
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Authors' reply
Authors: M. Niinimaki, O. Heikinheimo
Journal: BMJ (2011)

<h3>Objectives</h3> Prompt diagnosis of acute coronary syndrome (ACS) remains a challenge, with presenting symptoms affecting the diagnosis algorithm and, consequently, management and outcomes. This study aimed to identify sex differences in presenting symptoms of ACS. <h3>Design</h3> Data were collected within a prospective cohort study (EPIHeart). <h3>Setting</h3> Patients with confirmed diagnosis of type 1 (primary spontaneous) ACS who were consecutively admitted to the Cardiology Department of two tertiary hospitals in Portugal between August 2013 and December 2014. <h3>Participants</h3> Presenting symptoms of 873 patients (227 women) were obtained through a face-to-face interview. Outcome measures: Typical pain was defined according to the definition of cardiology societies. Clusters of symptoms other than pain were identified by latent class analysis. Logistic regression was used to quantify differences in presentation of ACS symptoms by sex. <h3>Results</h3> Chest pain was reported by 82% of patients, with no differences in frequency or location between sexes. Women were more likely to feel pain with an intensity higher than 8/10 and this association was stronger for patients aged under 65 years (interaction P=0.028). Referred pain was also more likely in women, particularly pain referred to typical and atypical locations simultaneously. The multiple symptoms cluster, which was characterised by a high probability of presenting with all symptoms, was almost fourfold more prevalent in women (3.92, 95% CI 2.21 to 6.98). Presentation with this cluster was associated with a higher 30-day mortality rate adjusted for the GRACE V.2.0 risk score (4.9% vs 0.9% for the two other clusters, P&lt;0.001). <h3>Conclusions</h3> While there are no significant differences in the frequency or location of pain between sexes, women are more likely to feel pain of higher intensity and to present with referred pain and symptoms other than pain. Knowledge of these ACS presentation profiles is important for health policy decisions and clinical practice.
Drug Legalization, Harm Reduction, and Drug Policy
Authors: David W. Wilbur
Journal: Annals of Internal Medicine (1996)

Letters15 April 1996Drug Legalization, Harm Reduction, and Drug PolicyDavid W. Wilbur, MD, PhDDavid W. Wilbur, MD, PhDPettis Memorial Veterans Administration Hospital; Loma Linda, CA 92357Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-124-8-199604150-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:DuPont and Voth's defense of the status quo in drug policy [1] begs for some response. The selective use of statistics, especially those derived from a private source, is unconvincing. The insinuation that persons who disagree with current policy do so because of a personal drug habit is pejorative, cannot be clearly evaluated, and sidesteps the issues. In fact, several large groups have strong incentives to assert a need to maintain the current system, including persons making a living on the government side of the current “war on drugs” and those who profit by supplying drugs in ...REFERENCE1. DuPont RL, Voth EA. Drug legalization, harm reduction, and drug policy. Ann Intern Med. 1995; 123:461-5. Google Scholar Author, Article, and Disclosure InformationAffiliations: Pettis Memorial Veterans Administration Hospital; Loma Linda, CA 92357 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 April 1996Volume 124, Issue 8Page: 776KeywordsCirrhosisDrug policyDrugsHabitsMotivation ePublished: 15 August 2000 Issue Published: 15 April 1996 Copyright & PermissionsCopyright © 1996 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Co‐existence of cutaneous T‐cell lymphoma and B hairy cell leukemia
Authors: Rossella Paolini, Alessandro Poletti, Emilio Ramazzina, Chiara Menin, Maria Santacatterina, Marco Montagna, Laura Bonaldi, Annarosa Del Mistro, Sergio Zamboni, Emma D'Andrea
Journal: American Journal of Hematology (2000)

A primary cutaneous form of peripheral T-cell lymphoma (PTCL) and a low grade B-cell non-Hodgkin's lymphoma that was classified as a variant of hairy cell leukemia (HCL) were simultaneously diagnosed in a 79-year-old woman by both phenotypic and genotypic analyses. The coexistence of a T- and B-cell lymphoma in the same patient is rare, and, to our knowledge, this particular association has not been previously described. The patient was referred to our Department for evaluation of multiple cutaneous itchy, reddish plaques; laboratory analyses disclosed a lymphocytosis, that presented 6 years earlier. A bone marrow aspirate showed a 50% B-cell interstitial infiltrate, while a skin biopsy surprisingly revealed a PTCL. Clonality of both neoplastic processes was assessed by Southern blot analysis. The indolent clinical course of the cutaneous disease, and the low and stable number of circulating neoplastic T cells supported the diagnosis of a mycosis fungoides (MF)-like PTCL. Possible oncogenic events and/or putative underlying viral infections which could have played a role in the occurrence of B- and T-cell non-Hodgkin's lymphomas in the same patient are discussed. Am. J. Hematol. 64:197–202, 2000. © 2000 Wiley-Liss, Inc.
THE CHEMISTRY OF THE URINE IN DISEASES OF THE PANCREAS.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phenelzine overdose treated with dantrolene sodium
Authors: R. F. Kaplan
Journal: JAMA (1986)

THE INGESTION of a monoamine oxidase (MAO) inhibitor can induce a complex array of hypermetabolic signs, including hyperpyrexia, tachycardia, generalized muscle rigidity, tachypnea, metabolic acidosis, hypoxemia, and hypercapnia<sup>1</sup>(J. W. Katalavis, MD, oral communication, November 1984). Toxicity of MAO inhibitors has previously been treated with standard therapy, ie, gastric lavage with activated charcoal, magnesium citrate, alkalinization of urine, and general support. Similar fulminant hypermetabolic states, such as neuroleptic malignant syndrome (NMS) and malignant hyperthermia (MH), respond to dantrolene sodium. Although two brief reports have been published,<sup>2,3</sup>there has been no well-documented report of a fulminant hypermetabolic reaction to a MAO inhibitor that was treated with dantrolene sodium. We report a severe case of phenelzine (Nardil) overdose; the patient failed to respond to conventional therapy but dramatically improved with the administration of dantrolene sodium. <h3>Report of a Case</h3> A 33-year-old, 70-kg, well-developed man with a history of hypertension and
Experience with the implant of vascular access devices by medical oncologist in a non-surgical scenery.
Authors: Alfonso Revuelta, David Rodriguez, Sara Fernández, Clara Iglesias, David Gómez, Jorge Sánchez, Maria Del Pilar Solis Hernandez, Laura Faez, Luisa Sánchez Lorenzo, Alfredo Castillo, Paula Jiménez-Fonseca, Emilio Esteban
Journal: Journal of Clinical Oncology (2018)

e22202 Background: Totally implantable central venous catheters are widely used in the management of patients (pts) with malignant diseases in order to facilitate drug delivery for the new therapeutic protocols. These are based on continuous administration and higher doses of chemotherapeutic agents with relative phlebitis problems and supportive treatment. Staff of our department, specially trained on the routinely implant of central venous accesses were in charge of the procedure. The technique was carried out under local anesthesia in a special suite of day hospital, under strict aseptic measures without fluoroscopic control. Methods: From Sep 94 to January 2017, 1665 devices ( port-a-cath systems [PS]) were implanted in 1627 pts, with a median age of 50.5 yr ( range 14-81), and median K.I. 70% (50-100), female 982/male 683. Venous access: right interior jugular 983, left subclavian 316, right subclavian 333, left interior jugular 33. A thorax X-ray was performed after each procedure and in 216 pts prophylactic antibiotics were given. Results: The venous access remained implanted a median of 438 days (1- +2210). Complications occurred in 266 placements (16%): Infections 116 (7%); deep venous thrombosis 66 (4%) obstruction 10 (0.6%); malpositioned 16 (2%); fractures/migration 28 (1.7%); pneumothorax 6 (0.32%); local skin necrosis 7 (0.6%). Five hundred and twenty devices were removed, three hundred and forty-seven (66%) after completing planned therapy and 173 (34%) due to complications [Infections (92), migration (22), malposition (12), venous thrombosis (26), obstruction (11) and skin necrosis (10)]. Cost-effectiveness of venous catheters in a non surgical scenery compared to devices implanted by interventional vascular radiologists in operating room turned out to be 1000 euro cheaper for each device. Conclusions: Our experience suggests that implant of vascular access devices by medical oncologist in a non-surgical scenery has similar or even less complications and is more cost effective with regard to radiology suite and operating room placement procedures.
PERITONEAL SUPPORTS—LIGAMENTUM PERITONEI).
Authors: BYRON ROBINSON
Journal: JAMA (1895)

The lesser bag extends in young subjects from the cardiac end of the stomach to the pelvis and from the transverse fissure of the liver to the spleen. Beside this wide extension of the sac does not long remain. The cavity begins to loose its completeness at the lateral circumference during childhood. Coalescence encroaches upon its borders. Adhesions of its closely applied walls begin early on the lateral edges. This coalescence appears to me to be the result of local peritonitis. However, coalescence occurs in distinct localities of the lesser sac, so far as my examinations are concerned. These definite localities are: (<i>a</i>), the pars omenti colica; (<i>b</i>), the ligamentum phrenico-colicum; (<i>c</i>), the omentum colicum Halleri; (<i>d</i>), on the posterior surface of the ligamentum gastro-lienalis. So far as regards the pars omentum colicum, every anatomist knows that it coalesces. Its two double-bladed layers become adherent in early adult life. No
VALUE OF VIVISECTION TO BRAIN SURGERY.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Escherichia coli 0157:H7 Outbreak Linked to Commercially Distributed Dry-Cured Salami—Washington and California, 1994
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Outcome of hospitalized injured patients after institution of a trauma system in an urban area
Authors: R. J. Mullins
Journal: JAMA (1994)

<h3>Objective.</h3> —To determine if risk of death for hospitalized injured patients changes when an urban trauma system is implemented. <h3>Design.</h3> —An analysis of the risk of death in hospitalized injured patients in 1984 and 1985 (pretrauma system), 1986 and 1987 (early trauma system), and 1990 and 1991 (established trauma system) using hospital discharge abstract data. <h3>Setting.</h3> —A total of 18 acute care hospitals in the four-county area encompassing Portland, Ore. <h3>Patients.</h3> —A cohort of 70 350 hospitalized patients with at least one discharge diagnosis indicating injury. <h3>Main Outcome Measure.</h3> —Death during hospitalization. <h3>Results.</h3> —After the trauma system was established, 77% of patients in the region with an Injury Severity Score (ISS) of 16 or greater were admitted to level I trauma centers. More than 72% of patients with an ISS less than 16 were hospitalized in nontrauma centers. Risk of death for injured patients hospitalized at level I trauma centers declined after the trauma system was established (odds ratio, 0.65; 95% confidence interval, 0.51 to 0.81). Patients who died in trauma centers after institution of the trauma system were younger and had more severe injuries, and the majority died within 1 day of admission, whereas patients who died in nontrauma centers died a median of 5 days after admission. <h3>Conclusion.</h3> —Establishment of a trauma system shifted the more seriously injured patients to level I trauma centers, where there was a significant reduction in the adjusted death rate. (<i>JAMA</i>. 1994;271:1919-1924)
Progress Toward Elimination of Rubella and Congenital Rubella Syndrome—the Americas, 2003-2008
Journal: JAMA (2009)

In 2003, the Pan American Health Organization (PAHO) adopted a resolution calling for rubella and congenital rubella syndrome (CRS) elimination in the Americas by the year 2010. Elimination was defined as the interruption of endemic rubella virus transmission in all countries of North America, Central America, South America, and the Caribbean for more than 12 months and no occurrence of CRS cases attributed to endemic transmission. To accomplish this goal, PAHO developed a rubella and CRS elimination strategy (3) to 1) introduce rubella-containing vaccine (RCV) into routine vaccination programs of all countries for children aged 12 months and reach >/=95% coverage in all municipalities, 2) conduct a one-time mass campaign among adolescents and adults and periodic follow-up campaigns among children aged <5 years, and 3) integrate rubella surveillance with measles surveillance and initiate CRS surveillance. During 1998-2006, confirmed rubella cases decreased 98% (from 135,947 to 2,998) in the Americas. However, in 2007, rubella outbreaks with a total of 13,014 cases occurred in three countries (Argentina, Brazil, and Chile), primarily in males not included in previous vaccination campaigns. This report summarizes overall progress toward reaching the 2010 goal of eliminating rubella and CRS. With completion of campaigns in Argentina, Brazil, and Haiti, all countries will have implemented the recommended PAHO strategy by the end of 2008, with the expectation of reaching the 2010 rubella and CRS elimination goal.
Ninth Annual Symposium on Cancer Chemotherapy—Cancer Care: Information Through Application
Journal: JNCI Journal of the National Cancer Institute (1987)

Journal Article Ninth Annual Symposium on Cancer Chemotherapy—Cancer Care: Information Through Application Get access JNCI: Journal of the National Cancer Institute, Volume 79, Issue 3, September 1987, Page 609, https://doi.org/10.1093/jnci/79.3.609-b Published: 01 September 1987
Book Review A Text-book of Psychiatry for Students and Practitioners . By D. K. Henderson, M.D. (Edin.), F.R.F.P.S. (Glas.), F.R.C.P.E., and R. D. Gillespie, M.D. (Glas.), F.R.C.P. (Lond.), D.P.M. (Lond.). Fifth edition. 8°, cloth, 660 pp. London: Oxford University Press, 1940. $6.00.
Journal: New England Journal of Medicine (1940)
Informed consent.
Authors: A Lawson, J Cohen
Journal: BMJ (1993)

baseline.3A risk of hypotension could then be calculated.If the risk of developing first dose hypotension was divided into quarters (from low to high) the incidence of hypotension was 088% and 3-3% in the placebo group versus 4 1/% and 23 -7% in the enalapril group.The corresponding mortal- ity among the same patients, however, was 7/4% and 13-7% in the placebo group versus 8-2% and 15-6% in the enalapril group.These differences are consistent with the overall neutral result of the study and with no significant difference between treatment groups.Thus first dose hypotension after enalapril in this setting seems to identify patients with a high risk of death regardless of enalapril.Early death within 30 days seems to be related to the index infarct and the extent of myocardial injury and is not amenable to enalapril treatment.